Quantcast
Last updated on April 16, 2014 at 7:44 EDT

Latest MultiCell Technologies Inc. Stories

2014-03-20 08:30:23

WOONSOCKET, R.I., March 20, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of...

2014-01-15 08:28:43

WOONSOCKET, R.I., Jan. 15, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death. This patent application describes a novel class of very small noncoding double stranded RNA molecules (VSRNAs) which interfere with the basic homeostatic cellular processes in tumor cells....

2013-11-13 08:29:18

WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a second U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. This...

2013-10-02 08:28:44

WOONSOCKET, R.I., Oct. 2, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and...

2013-08-06 08:33:30

WOONSOCKET, R.I., Aug. 6, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and Genisphere LLC will collaborate on the development of targeted MCT-485 nanoparticle therapeutics for the treatment of liver cancer. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. Hepatocellular carcinoma is the most common form of primary liver cancer, and...

2013-05-16 08:27:36

WOONSOCKET, R.I., May 16, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. Hepatocellular carcinoma is the most common form of primary liver cancer, and is a...

2012-12-26 08:20:56

WOONSOCKET, R.I., Dec. 26, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) presented at the 2012 American Society for Cell Biology® (ASCB®) Annual Meeting in San Francisco, CA, on Tuesday, December 18. Simona Bot, M.D. presented preclinical research results in an abstract titled "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma." This research was supported by MultiCell via a...

2012-10-22 19:20:55

SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (MCET.OB), a clinical-stage biopharmaceutical company, has added Grant G. Miller to its board of directors. Mr. Miller will replace Mr. Altig who will be stepping down to allow for this appointment. Mr. Miller received his B.A. from Loma Linda University in Riverside, CA and an MBA; Finance from the University of San Diego, in San Diego, CA. Mr. Miller currently serves as Chief Financial & Operating Officer of Sandel...

2012-09-27 02:26:45

WOONSOCKET, R.I., Sept. 27, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the acceptance by the American Society for Cell Biology® (ASCB®) of abstract "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma." The preclinical research results will be presented by Anand Ghanekar M.D., Ph.D., Division of Cellular & Molecular Biology, Toronto General...

2012-08-14 06:28:24

SAN DIEGO, Aug. 14, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTCBB: MCET.OB), a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer, announced the results from its annual shareholders meeting held Friday, August 10, 2012 in San Diego, CA. Jerry Newmin, Chairman and CEO, welcomed attendees, introduced the board of directors, officers and...